Early Progression in Non-Small Cell Lung Cancer (NSCLC) with High PD-L1 Treated with Pembrolizumab in First-Line Setting: A Prognostic Scoring System Based on Clinical Features

Early Progression in Non-Small Cell Lung Cancer (NSCLC) with High PD-L1 Treated with Pembrolizumab in First-Line Setting: A Prognostic Scoring System Based on Clinical Features

Background: Pembrolizumab is approved in monotherapy for the first-line (1L) of advanced or metastatic NSCLC patients with high PD-L1 (≥50%). Despite a proportion of patients achieve long-term survival, about one-third of patients experience detrimental survival outcomes, including early death, hype...

Full description

Bibliographic Details
Main Authors: Antonio Passaro, Silvia Novello, Diana Giannarelli, Emilio Bria, Domenico Galetta, Alain Gelibter, Maria Lucia Reale, Simona Carnio, Emanuele Vita, Alessio Stefani, Pamela Pizzutilo, Valeria Stati, Ilaria Attili, Filippo de Marinis
Format: Article
Language:English
Published: MDPI AG 2021-06-01
Series:Cancers
Subjects:
immunotherapy
pleural metastasis
corticosteroid
prognosis
detrimental effect
NSCLC
Online Access:https://www.mdpi.com/2072-6694/13/12/2935

Internet

https://www.mdpi.com/2072-6694/13/12/2935

Similar Items